Free Trial

Lakeshore Biopharma Q2 2024 Earnings Report

Lakeshore Biopharma logo
$2.24 -0.16 (-6.46%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lakeshore Biopharma EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Lakeshore Biopharma Revenue Results

Actual Revenue
$13.64 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Lakeshore Biopharma Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Lakeshore Biopharma Earnings Headlines

LakeShore Biopharma’s Financial Leap and Rabies Vaccine Trial Approval
Watch This Robotics Demo Before March 17th
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
See More Lakeshore Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lakeshore Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lakeshore Biopharma and other key companies, straight to your email.

About Lakeshore Biopharma

Lakeshore Biopharma (NASDAQ:LSB) Co., Ltd. engages in the provision of discovering, developing, manufacturing, and commercializing vaccines and therapeutic biologics for infectious diseases and cancer. It focuses on developing PIKA technology platform. It operates through the People's Republic of China and Other Countries or Regions. The company was founded by Yi Zhang on November 16, 2020 and is headquartered in Beijing, China.

View Lakeshore Biopharma Profile

More Earnings Resources from MarketBeat